355 related articles for article (PubMed ID: 16224276)
1. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
[TBL] [Abstract][Full Text] [Related]
2. Transient T cell depletion causes regression of melanoma metastases.
Rasku MA; Clem AL; Telang S; Taft B; Gettings K; Gragg H; Cramer D; Lear SC; McMasters KM; Miller DM; Chesney J
J Transl Med; 2008 Mar; 6():12. PubMed ID: 18334033
[TBL] [Abstract][Full Text] [Related]
3. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
4. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
[TBL] [Abstract][Full Text] [Related]
5. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
6. Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.
Baur AS; Lutz MB; Schierer S; Beltrame L; Theiner G; Zinser E; Ostalecki C; Heidkamp G; Haendle I; Erdmann M; Wiesinger M; Leisgang W; Gross S; Pommer AJ; Kämpgen E; Dudziak D; Steinkasserer A; Cavalieri D; Schuler-Thurner B; Schuler G
Blood; 2013 Sep; 122(13):2185-94. PubMed ID: 23958949
[TBL] [Abstract][Full Text] [Related]
7. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.
Telang S; Rasku MA; Clem AL; Carter K; Klarer AC; Badger WR; Milam RA; Rai SN; Pan J; Gragg H; Clem BF; McMasters KM; Miller DM; Chesney J
BMC Cancer; 2011 Dec; 11():515. PubMed ID: 22165955
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with denileukin diftitox (ONTAK).
Foss F
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
[TBL] [Abstract][Full Text] [Related]
10. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
Olsen E; Duvic M; Frankel A; Kim Y; Martin A; Vonderheid E; Jegasothy B; Wood G; Gordon M; Heald P; Oseroff A; Pinter-Brown L; Bowen G; Kuzel T; Fivenson D; Foss F; Glode M; Molina A; Knobler E; Stewart S; Cooper K; Stevens S; Craig F; Reuben J; Bacha P; Nichols J
J Clin Oncol; 2001 Jan; 19(2):376-88. PubMed ID: 11208829
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
Kadin ME; Vonderheid EC
Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
[No Abstract] [Full Text] [Related]
12. Optimizing denileukin diftitox (Ontak) therapy.
Duvic M; Talpur R
Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
[TBL] [Abstract][Full Text] [Related]
13. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
Chin KM; Foss FM
Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
[TBL] [Abstract][Full Text] [Related]
14. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
Wong BY; Gregory SA; Dang NH
Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
[TBL] [Abstract][Full Text] [Related]
15. The IL-2 diphtheria toxin fusion protein denileukin diftitox modulates the onset of diabetes in female nonobese diabetic animals in a time-dependent manner and breaks tolerance in male nonobese diabetic animals.
Zinser E; Rössner S; Littmann L; Pangratz N; Schuler G; Steinkasserer A
J Immunol; 2012 Aug; 189(3):1173-81. PubMed ID: 22730534
[TBL] [Abstract][Full Text] [Related]
16. Denileukin diftitox: a concise clinical review.
Eklund JW; Kuzel TM
Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
[TBL] [Abstract][Full Text] [Related]
17. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
de Vries IJ; Castelli C; Huygens C; Jacobs JF; Stockis J; Schuler-Thurner B; Adema GJ; Punt CJ; Rivoltini L; Schuler G; Coulie PG; Lucas S
Clin Cancer Res; 2011 Feb; 17(4):841-8. PubMed ID: 21177412
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
[TBL] [Abstract][Full Text] [Related]
19. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
Litzinger MT; Fernando R; Curiel TJ; Grosenbach DW; Schlom J; Palena C
Blood; 2007 Nov; 110(9):3192-201. PubMed ID: 17616639
[TBL] [Abstract][Full Text] [Related]
20. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).
Talpur R; Apisarnthanarax N; Ward S; Duvic M
Leuk Lymphoma; 2002 Jan; 43(1):121-6. PubMed ID: 11908715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
